Penumbra, Inc. (PEN)
NYSE: PEN · Real-Time Price · USD
339.61
-0.55 (-0.16%)
At close: Mar 4, 2026, 4:00 PM EST
339.61
0.00 (0.00%)
After-hours: Mar 4, 2026, 4:10 PM EST
Penumbra Employees
Penumbra had 4,700 employees as of December 31, 2025. The number of employees increased by 200 or 4.44% compared to the previous year.
Employees
4,700
Change (1Y)
200
Growth (1Y)
4.44%
Revenue / Employee
$298,652
Profits / Employee
$37,806
Market Cap
13.33B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 4,700 | 200 | 4.44% |
| Dec 31, 2024 | 4,500 | 300 | 7.14% |
| Dec 31, 2023 | 4,200 | 300 | 7.69% |
| Dec 31, 2022 | 3,900 | 100 | 2.63% |
| Dec 31, 2021 | 3,800 | 500 | 15.15% |
| Dec 31, 2020 | 3,300 | 600 | 22.22% |
| Dec 31, 2019 | 2,700 | 500 | 22.73% |
| Dec 31, 2018 | 2,200 | 500 | 29.41% |
| Dec 31, 2017 | 1,700 | 200 | 13.33% |
| Dec 31, 2016 | 1,500 | 400 | 36.36% |
| Dec 31, 2015 | 1,100 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Koninklijke Philips | 65,340 |
| Smith & Nephew | 18,060 |
| STERIS | 17,787 |
| Zimmer Biomet Holdings | 17,000 |
| DexCom | 11,100 |
| Bio-Rad Laboratories | 7,450 |
| Bio-Rad Laboratories | 7,450 |
| Globus Medical | 6,000 |
PEN News
- 7 days ago - Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire
- 19 days ago - Allspring Growth Fund Q4 2025 Fund Performers And Detractors - Seeking Alpha
- 4 weeks ago - Boston Scientific announces results for fourth quarter and full year 2025 - PRNewsWire
- 5 weeks ago - Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewsWire
- 5 weeks ago - Artisan Small Cap Fund Q4 2025 Portfolio Activity - Seeking Alpha
- 6 weeks ago - Boston Scientific to buy Penumbra in $14.5B deal to expand cardiovascular reach - Invezz
- 6 weeks ago - Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. - Barrons
- 6 weeks ago - Boston Scientific is buying Penumbra for $14.5 billion, gaining entry to ‘fast-growing' vascular segments - Market Watch